Morepen laboratories has submitted a compliance report to the National Stock Exchange and BSE Limited regarding the status of physical share transfer re-lodgement requests under SEBI's special window provision. The report, dated January 28, 2026, provides details on transfer requests processed during the initial period of the special window.

SEBI Special Window Compliance

The submission was made in accordance with SEBI Circular No. SEBI/HO/MIRSD/MIRSD-PoD/P/CIR/2025/97 dated July 2, 2025. This circular granted a special 6-month window for re-lodgement of physical share transfer requests, running from January 1, 2026 to June 30, 2026. The current report covers the initial period from January 1 to January 6, 2026.

Transfer Request Status Summary

The status report was prepared by MAS Services Limited, the company's Registrar and Share Transfer Agent. The report provides a comprehensive breakdown of transfer request activities during the specified period.

Registrar and Transfer Agent Details

MAS Services Limited, serving as the Registrar to Issue and Share Transfer Agent, confirmed the status as of the reporting period. The company is registered with CIN U74899DL1973PLC006950 and operates from its registered office at T-34, 2nd Floor, Okhla Industrial Area, Phase-II, New Delhi.

Corporate Communication

The report was signed by Vipul Kumar Srivastava, Company Secretary (F-12148), and submitted to both stock exchanges where Morepen Laboratories shares are listed. The company trades on NSE under the symbol MOREPENLAB and on BSE with scrip code 500288.

Company Information

Morepen Laboratories Limited operates with CIN L24231HP1984PLC006028. The company maintains its corporate office at Tower C, DLF Cyber Park, Gurugram, Haryana, while its registered office is located at Morepen Village, Baddi, Himachal Pradesh. This regulatory filing demonstrates the company's commitment to maintaining transparency and compliance with SEBI regulations regarding physical share transfers.

Morepen Laboratories has secured a significant legal victory by obtaining a stay on a show-cause notice from the Himachal Pradesh High Court, providing relief in a GST refund dispute worth ₹117.94 crore. The pharmaceutical company successfully challenged the notice through legal proceedings, ensuring continuity of its business operations without immediate financial impact.

Legal Proceedings and Court Order

The Central GST & Central Excise Commissionerate in Shimla had issued a show-cause notice dated December 2, 2025, alleging violations of GST regulations. The notice claimed that Morepen Laboratories had erroneously claimed excess GST refunds, violating Section 54 of the CGST Act, 2017, and Rule 89 of the CGST Rules, 2017.

In response to the allegations, Morepen Labs filed a writ petition before the High Court of Himachal Pradesh in Shimla. The court reviewed the matter and passed an order on January 6, 2026, granting a stay on the operation of the show-cause notice.

Business Impact Assessment

According to the company's official statement, the high court's stay order ensures no immediate adverse effects on its operations. The management has confirmed that the legal relief provides protection across multiple business dimensions:

• Financial Operations: No immediate impact on cash flows or financial position
• Business Activities: Continued normal operations without disruption
• Operational Continuity: All business functions remain unaffected

Recent Financial Performance

Morepen Laboratories had reported mixed financial results for Q2FY2025-26, showing revenue challenges but improved profitability metrics.

Despite revenue declines, the company demonstrated strong profit recovery with net profit surging significantly on both quarterly and annual comparisons.

Market Response

The company's stock price reflected market sentiment on the trading day, closing at ₹40.32, representing a decline of ₹1.20 or 2.89% from the previous session. The legal stay provides a foundation for operational stability while the GST matter remains under judicial review.